Cardiovascular disease diagnostics a global Strategic Business Report




Дата канвертавання24.04.2016
Памер85.33 Kb.
窗体顶端


CARDIOVASCULAR DISEASE DIAGNOSTICS - A Global Strategic Business Report


联系购买电话:010-82863480 公司名称:佐思信息 公司地址:北京市海淀区苏州街18号院长远天地大厦A2座 1008-1室(100080)

出版日期:February 2011

This report analyzes the worldwide markets for Cardiovascular Disease Diagnostics in US$ Million by the following product segments - Annual estimates and forecasts are provided for the period 2007 through 2015. Also, a seven-year historic analysis is provided for these markets. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, Middle East, and Latin America. The report profiles 71 companies including many key and niche players worldwide such as AccuTech, LLC, Abbott Diagnostics, Alere Inc., Biosite, Inc., Ani Biotech Oy, Axis-Shield PoC, Beckman Coulter, Inc., biom閞ieux, Cambridge Heart, Inc., Cholestech Corp., GE HealthCare, Home Access Health Corporation, LifeSign LLC, Liposcience, Inc., Nanosphere, Inc., Ortho-Clinical Diagnostics, Inc., Philips Healthcare, Polymer Technology Systems, Inc., Response Biomedical Corp., Roche Diagnostics, Siemens Healthcare Diagnostics, Inc., St. Jude Medical, Inc., and EP MedSystems. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

 TABLE OF CONTENTS  

  CARDIOVASCULAR DISEASE DIAGNOSTICS (Complete Report) Pages : 477   |

 1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS.......13   

  Study Reliability and Reporting Limitations.......1  

  Disclaimers.......2  

  Data Interpretation & Reporting Level.......3

Quantitative Techniques & Analytics.......3

Product Definitions and Scope of Study.......3

In Vitro Diagnostics.......3

In Vivo Diagnostics.......3  

 2. INDUSTRY OVERVIEW.......56   

  Cardiovascular Diseases: The Undying Challenge.......51

  Table 1: Region-Wise Incidence and Prevalence of Cardiovascular Diseases in 2006.......6

Mounting Healthcare Costs - Calls for Early Diagnosis.......6

Cardiovascular Disease Diagnostics: Playing a Pivotal Role in Early Disease

  Detection.......61

  Developed Countries Dominate, Developing to be the Future Growth Engine.......7

Fast and Accurate Diagnosis ?Reduce Unnecessary Healthcare Costs.......71

  POC Diagnostics Market Gains Momentum.......8

Cardiac Markers - Making Diagnosis Easier and Quicker.......81

  Major Cardiac Markers and their Properties.......9

What抯 New in POC Cardiac Markers Space?.......91

  Leading Players.......10

List of Point of Care Cardiac Marker Testing Products.......101

 3. IN-VIVO DIAGNOSTICS.......114   

  Table 2: Global In-vivo Cardiovascular Disease Diagnostics Market by Region: 2010 (includes corresponding Graph/Chart).......11

Novel Imaging Techniques Boost In vivo Diagnostics Market.......111

  Non-Invasive Procedure Hogs the Limelight for Cardiovascular Treatment.......12

Cardiology Diagnostic Imaging.......12

New Technologies Bring Diagnostics Closer to Patients.......121

  Trends Cited in the Imaging Technologies Market.......13

CT Scanners.......131

  MRI.......14

Move Towards Efficient Patient Data Management.......141

 4. IN-VITRO DIAGNOSTICS.......156   

  A Quick Insight into the Global In-vitro Diagnostics Market.......15

Growth Trends.......15

Developed Countries Drive In-Vitro Diagnostics (IVD) Market.......151

  Table 3: Leading In-Vitro Diagnostics Markets Worldwide (2007): Percentage Breakdown for North America, Europe, Japan, and Others (includes corresponding Graph/Chart).......16

Established Players Dominate the Fragmented Market.......16

Table 4: Leading Players in the Global In-Vitro Diagnostics Market (2009): Percentage Breakdown of Value Sales for Roche Diagnostics, Abbott Diagnostics, Ortho/ LifeScan, Bayer/Siemens, Beckman Coulter, BD, Dade Behring, bioMerieux and Others (includes corresponding Graph/Chart).......161

  Point-of-Care In-Vitro Testing on the Roll.......17

Table 5: Global In vitro Diagnostics Market by Type of Test (2007): Percentage Breakdown for Central Lab Testing, Point-of-Care Testing, and Molecular Testing (includes corresponding Graph/Chart).......17

A Specific Focus on Global Cardiovascular In-Vitro Diagnostics Market.......171

  Market Analysis.......18

Table 6: World Cardiovascular In-vitro Diagnostics Market: 2010 (includes corresponding Graph/Chart).......18

Aging Population Drives Home Testing Market.......181

  Cholesterol and Other Cardiovascular Test Kits Offered by Leading Companies.......19

Development of Home Cholesterol Testing Kits.......19

Table 7: Global Cholesterol Point-of-Care Rapid Tests Market (2009): Market Shares of Leading Players by Value Sales for Inverness Medical, Roche, Abaxis, and Others (includes corresponding Graph/Chart).......19

Strong Demand for Risk Assessment Markers.......191

  Advancements in Alternate-Site Coagulation Monitoring.......201

 5. CVD - CAUSE AND RISK FACTORS.......217   

  CVD - Global Facts.......21

Table 8: CVD Death Rates (per 100,000 population) Among Men (Aged 35-74 years) by Select Country: 2007 (includes corresponding Graph/Chart).......211

  Table 9: CVD Death Rates (per 100,000 population) Among Women (Aged 35-74 years) by Select Country: 2007 (includes corresponding Graph/Chart).......22

Atherosclerosis - Leading Cause for CVD.......22

Risk Factors.......22

Irreversible Risk Factors.......22

Increasing age.......221

  Sex (gender).......23

Heredity (including Race).......23

Risk Factors that can be controlled.......23

Tobacco Smoke.......23

High Blood Cholesterol.......231

  LDL Cholesterol.......24

HDL Cholesterol.......24

Triglyceride levels.......241

  Hypercholesterolemia - Conditions Associated with Cholesterol Level.......25

High Blood Pressure.......251

  BP - Leading Cause of Cardiovascular Disease in Young Adults.......26

Physical Inactivity.......26

Obesity and Overweight.......26

Diabetes Mellitus.......26

Cardiovascular Disease and Homocysteine Levels.......261

  Measures for Reducing Cardiovascular Diseases.......271

 6. CARDIOVASCULAR DISEASE AND CONDITIONS.......283   

  Angina Pectoris.......28

Arrhythmias.......28

Sudden Cardiac Death (SCD).......28

Stroke.......281

  Congestive Heart Failure.......29

Heart Failure Classification as per the NYHA and ACC/AHA.......291

  Table 10: Prevalence Rates of Congestive Heart Failure in Select Countries (per 10,000) (includes corresponding Graph/Chart).......30

Cardiovascular Disease Involving Transplant Patients.......301

 7. DIAGNOSTIC TESTS FOR CARDIOVASCULAR DISEASES.......3112   

  In-Vitro Cardiovascular Diagnostics.......31

Cholesterol Testing.......31

Use of Markers.......31

Creatine Kinase MB.......311

  Troponin T and Troponin I.......32

C-Reactive Protein.......321

  Plasminogen Activator Inhibitor-1.......33

D-Dimer.......33

Thrombus Precursor Protein.......33

Other Cardiac Markers.......33

Increasing Popularity of Risk Assessment Markers.......331

  A Step Forward in Cardiovascular Risk Assessment.......34

In Vivo Diagnostic Tests.......34

Computed Imaging / Tomography.......34

Electron Beam Computed Tomography (EBCT).......341

  Appropriate Conditions for EBCT Diagnosis.......35

Cardiac Positron Emission Tomography (PET).......351

  Digital Cardiac Angiography/ Digital Subtraction Angiography.......36

Magnetic Resonance Imaging (MRI).......361

  Single Photon Emission Computed Tomography (SPECT).......37

Echocardiography.......37

Different Types of Echo-techniques.......37

M-mode (Motion mode, One-dimensional).......371

  Two-Dimensional (Cross-sectional).......38

Stress Echocardiogram (Stress Echo).......38

Transesophageal Echocardiogram (TEE).......38

Risks.......38

Ultrasound Tests.......38

Doppler Ultrasound.......381

  Intravascular Ultrasound.......39

Working.......39

Comparative Facts Related to Definitive Diagnosis of Cardiovascular Disease.......391

  Nuclear Cardiology Tests.......40

Applications.......40

Types of Nuclear Cardiology Tests.......40

Myocardial Perfusion Imaging.......401

  Applications.......41

Risks.......41

Ventricular Function Test.......411

  Testing Cardiac Stress.......42

Cardio Vascular Disease Diagnostics Tests in the Pipeline.......42

Aderis MRE-0470.......42

CardioMEMS Novel Technology.......42

Technology Platform.......421

 8. PRODUCT LAUNCHES AND DEVELOPMENTS.......436   

  Cardiac Science Launches Microvolt T-Wave Alternans Module.......43

Cleveland HeartLab to Extend Test Menu.......43

St. Jude Medical Introduces EnSite Derexi Module.......431

  NorDiag Unveils NorDiags Arrow Instrument.......44

Biosense Webster Launches CARTO?3 System.......44

McKesson Unveils New Variant of Horizon Cardiology Cardiovascular Information

  System.......44

Correlagen Launches CardioGeneScan Test.......441

  Royal Philips Electronics to Launch PageWriter TC50 Cardiograph.......45

Philips Introduces Xcelera R3.1.......45

St. Jude Medical Launches Medical Devices for Heart Rhythms Disorders.......451

  TomTec and Medis Launches Cardiac Imaging and Analysis Product.......46

Royal Philips Electronics Launches PageWriter TC70.......461

  Philips Healthcare to Introduce CX50 CompactXtreme.......47

Royal Philips Electronics Introduces Xcelera R2.2.......47

Toshiba America to Launch AplioTM Artida.......472

 9. PRODUCT LAUNCHES AND DEVELOPMENTS IN THE RECENT PAST - A PERSPECTIVE

  BUILDER.......4918   

  Philips Rolls Out 256-slice CT scanner, Brilliance iCT Scanner.......49

Royal Philips Launches Live 3D Transesophageal Echocardiogram Probe.......49

GE Healthcare Launches Vivid e Ultrasound Systems.......49

Cardionetics Launches ECG Monitor for 24-Hour Real-Time Cardiac Diagnosis.......491

  Siemens Launches Imaging Release for the ACUSON Sequoia Platform.......50

GE Healthcare Launches Version 2.0 of Centricity Cardiology CA1000.......50

GE Healthcare Introduces New Capabilities to CardioSoft Diagnostic Software.......50

GE Healthcare抯 Lightspeed VCT Offers Imaging at 70% Lower Exposure.......501

  Roche Diagnostics Launches cobas h 232 Portable Cardiac Marker System (Outside

  US).......51

Royal Philips Launches New Imaging Tool for Complex Cardiac Arrhythmias.......51

Siemens Medical Introduces syngo?US, New Echocardiography Solution........51

Dade Behring Introduces CardioPhase?hsCRP Test for Multiple Testing

  Platforms........511

  Shimadzu Launches Two Models in Angiographic Imaging.......52

Omron Healthcare Introduces Non Invasive Vascular Profiling System.......52

Abbott Launches XIENCE V, New Coronary Stent System.......52

Siemens Medical Introduces Acuson AcuNav 8F, an Advanced Ultrasound Catheter .......521

  BioM閞ieux Introduces High Performance VIDAS Troponin I Ultra.......53

Siemens Launches Acuson X300 Ultrasound Platform.......53

Siemens Releases Web-Enabled CT.......531

  GE Introduces Latest Electrocardiograph Device, MAC 3500.......54

GE Emphasizes on the Striking Features of New Vivid 7 Dimension ?6.......54

GE Launches Latest Innova Digital Flat Panel Biplane Imaging Devices.......541

  Medtronic Introduces Latest Range of Implantable Cardiac Defibrillators.......55

Philips Introduces Web Based Cardiac Tools.......55

Siemens Showcases Solutions for Cardiac Problems Through Molecular Imaging.......55

Siemens Presents Advancements in Echocardiography.......551

  Siemens Debuts syngo BEAT.......56

Siemens Combines syngo?Dynamics with Soarian? for Cardiovascular EPR.......56

GE Healthcare Unveils CardIQ Fusion.......56

GE Introduces Discovery VCT.......56

GE Unveils Dynamic VUE.......561

  GE Launches CardIQ Xpress.......57

GE Presents the Ventri for Cardiac Imaging.......57

GE Introduces High Definition Magnetic Resonance System.......57

Dade Behring Unveils CardioPhase(R) hsCRP Test.......57

Siemens Launches Encompass III on C512 Ultrasound Platform.......571

  Siemens Launches Four New CT Clinical Engines.......58

Omron Launches HEM-9000AI Cardiovascular Diagnostic Tool.......58

Corgenix Introduces Predictive Cardiovascular Diagnostic Kit, AtherOx?......58

Philips Introduces HD11 XE Cardiology Ultrasound System.......581

  Siemens Introduces Biplane FD Cardiology System.......59

Siemens Introduces Syngo Circulation Software for CT Tomography.......59

Siemens Introduces SOMATOM Definition for Cardiac Imaging.......59

Dade Behring Unveils Homocysteine Test on BN (TM) Systems.......59

Roche Unveils Cardiac pro-BNP Test.......591

  Philips Introduces HD11 XE.......60

Corgenix Unveils AtherOx(TM).......60

GE Healthcare Unveils Breakthrough Imaging Technology.......60

Philips Launches Products to Detect Heart Problems.......601

  Philips Unveils Computed Tomography and EP Planning package.......61

Philips Widens Magnetic Resonance Portfolio.......61

New Cardiac Monitoring Products from Philips.......61

Siemens Launches Image-Arena.......61

Siemens Announces New Procam-Calculator Combined with CT Examination.......611

  Siemens Medical Solutions Launches Axiom Artis dTA.......62

GE Healthcare Unveils Vivid i.......621

  GE Healthcare Presents Fully Integrated 4D Cardiovascular Ultrasound System.......63

GE Healthcare Debuts New Imaging System.......63

New Discovery PET/CT Systems from GE Healthcare.......63

SonoSite Presents SonoCalc IMT Software.......631

  Dade Behring Introduces High Sensitivity Troponin I Assay.......64

Biosite Unveils New Diagnostic Test.......64

MDS Diagnostic Services Unveils New Test to Prevent Heart Disease.......641

  diaDexus Develops PLAC Test.......65

Siemens Introduces New Nuclear Cardiology Imaging System.......65

Roche Diagnostics Receives U.S. Clearance and European CE Mark.......651

  Camtronics Unveils Cardiovascular Screening Software.......66

Mayo Pioneers New Enzyme-Based Cardiovascular Risk Assessment Test.......661

 10. RECENT INDUSTRY ACTIVITY.......679   

  Inverness Changes Name to Alere.......67

Miraculins Acquires PreMD抯 PREVU(i) Skin Cholesterol Test Assets.......67

Kardia Health Systems Partners with TomTec Imaging Systems.......67

TriLink and Biofortuna Ink Licensing Agreement.......671

  Corgenix Enters into a Strategic Alliance with ELITech.......68

VaxGen to Merge with diaDexus.......68

St. Jude Medical to Take Over LightLab Imaging.......681

  GE Healthcare and CardioDx Enter into Strategic Alliance.......69

bioMerieux and Knome Ink Strategic Partnership Agreement.......69

Merge Healthcare Acquires AMICAS.......691

  Diamedix and Nova Ink Distribution Agreement.......70

Inverness Acquires Standard Diagnostics.......70

Quidel Acquires Diagnostic Hybrids.......70

bioM閞ieux Acquires Meikang Biotech.......701

  Aurora Health Care Partners with Celera.......71

Mediscience Technology Corporation Acquires SensiVida Medical Systems.......71

Volcano Acquires Axsun Technologies.......71

Thermo Fisher Takes Over B.R.A.H.M.S........711

  SonoSite Acquires CardioDynamics International.......72

IntriCon Snaps Up Datrix.......72

ST. Jude Medical Receives US FDA and European Approval for EnSite Velocity?Cardiac

  Mapping System.......72

Roche Inks Agreement with Response Biomedical.......721

  Dynatek Dalta Scientific Inks Agreement with State Food and Drug

  Administration.......73

Amic Inks Licensing Deal with Roche Diagnostics.......73

TRICARE Includes Atherotech抯 VAP?Test.......731

  PreMD Receives NSE Letter from US FDA for POC Skin Cholesterol Test.......74

Amic Gains License for Roche抯 Cardiac Marker.......74

diaDexus and Fisher HealthCare Sign Agreement.......741

  Inverness Inks Distribution Agreement with PrognostiX.......75

GE Healthcare Enters into Collaboration with Boston Scientific.......75

St. Jude Medical Acquires EP MedSystems.......751

 11. INDUSTRY ACTIVITY IN THE RECENT PAST - A PERSPECTIVE BUILDER.......7616   

  Inverness Takes Over Biosite.......76

Siemens Medical Acquires Dade Behring.......76

Inverness Medical Innovations Acquires Cholestech.......761

  Acrongenomics, Pearson and Molecular Enter into Joint Venture.......77

Cholestech Teams Up with Onsite Health Diagnostics.......77

Lipomics to Collaborate with Agilent Technologies to Develop Diagnostic Tests........771

  Transgenomic and Fiuotecnica Renew Collaboration Agreement.......78

Alteon and BioRap Technologies Enter into an Agreement.......78

IM Medical Acquires New Technology for Detecting Cardiovascular Diseases.......78

Medtronic Establishes New Business Entity.......781

  Siemens Medical Acquires Bayer Healthcare抯 Diagnostics Unit.......79

Inverness Medical Innovations Completes Acquisition of HemoSense.......79

Spacelabs Acquires Ferraris?Cardiac Unit.......791

  Global Immune Takes over Primedical International.......80

Siemens Acquires Diagnostics Products.......80

Cholestech and Life Line Enter into Collaboration.......80

LipoScience Signs an Agreement with ARUP.......80

Philips Acquires Witt Biomedical.......801

  CardioDynamics Enters into an OEM Agreement with Shenzhen Mindray.......81

Biosense Enters into Strategic Partnership with Siemens Medical Solutions.......81

Dade Behring Approved the Use of FSAP Antibodies by American Diagnostica.......81

Abbott Receives Non-exclusive Sublicense for Diagnostic Use of PIGF.......811

  Nanogen Acquires Spectral抯 Cardiac Test Division.......82

Varian Enters into Alliance with LipoScience to Jointly Develop NMR System.......82

Cardiac Services Professionals Establish eCardio Diagnostics.......821

  Response Biomedical Wins Nonexclusive License Rights for NT-proBNP and Troponin

  T.......83

Biomerieux gains Nonexclusive License for NT-proBNP.......83

Philips and PMI Ink an Agreement for Outpatient Facility.......83

LipoScience Enters into an Agreement with LabCorp.......83

Abbott and Cleveland Clinic to Co-develop Myeloperoxidase Cardiac Test.......831

  Abbott Receives 510(k) Clearance from FDA for Myoglobin Test.......84

FDA Clears Additional Claim for Biosite抯 Triage (R) BNP Test.......84

Biosite Inks an Agreement with University of Mainz.......84

Dade Behring Receives FDA Clearance for Advanced D-Dimer Assay.......84

Nanogen Acquires SYN昘 Pharma.......841

  GE Takes Over Amersham Plc.......85

St. Jude Medical Acquires Irvine Biomedical and Epicor.......85

SonoSite Snaps Up SonoMetric.......85

CardioDynamics Acquires Vermed.......85

Philips and EP MedSystems Announce an Alliance Involving Electrophysiology

  Solutions.......85

Toshiba and ViTAL Enters into an Alliance with Johns Hopkins University School of

  Medicine.......851

  Response Biomedical Collaborates with Shionogi.......86

Terumo Signs Agreement with Spencer Technologies.......86

Spectral Diagnostics Announces Agreement with NGC Medical.......86

Philips Signs Agreement with Fletcher Allen Health Care.......86

Spectral Diagnostics Enters into an Agreement with Cardinal Health.......86

Siemens Signs Agreement with MediGuide.......861

  Biosite Enters into Agreement with DMI BioSciences.......87

Cambridge Heart Enters into Agreement with Del Mar Reynolds.......87

Cholestech Enters into an Agreement with Itamar Medical.......87

Siemens Enters into a Contract with HiPGraphics.......871

  Abbott Announces US Clearance for Axis-Shield抯 BNP Test for Use on AxSYM.......88

Cholestech Announces FDA 510(k) Approval for hs-CRP Test.......88

Dade Behring Bags FDA Clearance NT-proBNP Test.......88

Dade Behring Receives FDA Clearance for N High Sensitivity CRP Assay.......88

EP-4 Computerized Cardiac Stimulator Bags FDA Approval.......88

Biosite Adds two new offices.......881

  Bayer Diagnostics Enhances BNP Assay Offering Globally.......89

EP MedSystems Garners CE Approval for ALERT Deflectable CS Catheter in Europe.......89

Cambridge Heart Inc. and Quinton Cardiology Systems Renew Pact.......891

  EPIX and Schering AG Extends Collaboration Agreement.......90

Siemens Ultrasound and TomTec Imaging Systems Announces Agreement.......90

FIT Biotech Plc Acquires Xenerate Ab to Develop Innovative Cardiovascular

  Devices.......90

Beckman Coulter Enters into Agreement with Biosite.......901

  Dade Behring Garners Non-exclusive Rights for a Key Cardiac Marker.......91

Bracco Diagnostics Inc., Joins Hand with Eastern Isotopes Inc to Develop

  CardioGen-82?......91

New Lab Test from diaDexus Receives FDA Clearance.......91

Hypertension Diagnostics Receives SDA Approval in China.......911

 12. FOCUS ON SELECT GLOBAL PLAYERS.......9210   

  AccuTech, LLC (USA).......92

Abbott Diagnostics (USA).......92

Alere Inc. (USA).......922

  Biosite, Inc. (USA).......94

Ani Biotech Oy (Finland).......94

Axis-Shield PoC (UK).......941

  Beckman Coulter, Inc. (USA).......95

biom閞ieux (France).......95

Cambridge Heart, Inc. (USA).......951

  Cholestech Corp. (USA).......96

GE HealthCare (UK).......961

  Home Access Health Corporation (USA).......97

LifeSign LLC (USA).......97

Liposcience, Inc. (USA).......971

  Nanosphere, Inc. (USA).......98

Ortho-Clinical Diagnostics, Inc. (USA).......98

Philips Healthcare (USA).......981

  Polymer Technology Systems, Inc. (USA).......99

Response Biomedical Corp. (Canada).......991

  Roche Diagnostics (Switzerland).......100

Siemens Healthcare Diagnostics, Inc. (USA).......1001

  St. Jude Medical, Inc. (USA).......101

EP MedSystems (USA).......1011

 13. GLOBAL MARKET PERSPECTIVE.......102   

  Table 11: World Recent Past, Current & Future Market Analysis for Cardiovascular Disease Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1021

  Table 12: World Historic Review for Cardiovascular Disease Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East, and Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......1031

  Table 13: World 11-Year Perspective for Cardiovascular Disease Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).......1041

  Table 14: World Recent Past, Current & Future Market Analysis for Cardiovascular In Vitro Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1051

  Table 15: World Historic Review for Cardiovascular In Vitro Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......1061

  Table 16: World 11-Year Perspective for Cardiovascular In Vitro Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).......1071

  Table 17: World Recent Past, Current & Future Market Analysis for Cardiovascular In Vivo Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1081

  Table 18: World Historic Review for Cardiovascular In Vivo Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......1091

  Table 19: World 11-Year Perspective for Cardiovascular In Vivo Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).......1101

 14. THE UNITED STATES.......11112   

  A. Market Analysis.......111

Trends and Issues.......111

Innovations Drive the Usage of Cardiovascular Monitoring Systems.......111

Cholesterol POCT Market: An Overview.......1111

  Table 20: US Cholesterol Point-of-Care Testing (2009): Market Shares of Leading Players by Value Sales for Inverness Medical, Polymer Technology Systems, and Roche Diagnostics (includes corresponding Graph/Chart).......112

Increasing Cardiovascular Ailments Drive Sales of Home Test Devices.......112

CHF Biomarkers to Spearhead the US market.......1121

  Table 21: US AMI (Acute Myocardial Infarction) Diagnostics Market: Market Share by Revenue held by Major Players (Dade Behring, Beckman Coulter, Bayer Diagnostics, and Others) in 2006 (includes corresponding Graph/Chart).......113


Table 22: US CHF (Congestive Heart Failure) Diagnostics Market: Market Share by Revenue held by Major Players (Dade Behring, Beckman Coulter, Bayer Diagnostics, and Others) in 2006 (includes corresponding Graph/Chart).......113

Cardiovascular Disease Prevalence in the US.......1131

  Key Statistics on Cardiovascular Diseases.......114

Mortality Statistics.......1141

  Table 23: Prevalence of Cardiovascular Disease in the US (2004): A Historic Review (includes corresponding Graph/Chart).......115
Table 24: Percentage Breakdown of Deaths from Cardiovascular Diseases in the US (2004): A Historic Review (includes corresponding Graph/Chart).......1151

  Table 25: Prevalence of Cardiovascular Diseases among Americans by Age (Age 20 and Older) and Sex (2004): A Historic Review (includes corresponding Graph/Chart).......116


Table 26: A Factoid of CHD and MI (In Million) in the US (2003): A Historic Review.......116

Startling facts related to Stroke in US.......1161

  Table 27: A Factoid of Stroke (In Million) in the US (2003): A Historic Review.......117

Incidence of Coronary Heart Disease.......117

AHA Statistics for Coronary Heart Disease.......1171

  Mortality rates of CHD.......118

Table 28: Annual Number of Americans Having Diagnosed Heart Attack by Age and Sex (2004) (includes corresponding Graph/Chart).......1181

  Table 29: Prevalence of CHD by Age and Sex (2004) (In % population) (includes corresponding Graph/Chart).......119

Arrhythmias.......119

CAD Diagnostics.......1191

  PVD Diagnostics.......120

Medicare Reimbursement Set for CPT Code 83704.......120

Competitive Glance.......120

Point-of-Care (POC) Diagnostics Market in the US.......1201

  Table 30: Leading Players in the US POC Cardiac Market (2004) - Percentage Breakdown by Value Sales for Biosite, Dade Behring, Spectral Diagnostics, Roche and Others (includes corresponding Graph/Chart).......121

B. Market Analytics.......121

Table 31: US Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1211

  Table 32: US Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......122


Table 33: US 11-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2005, 2010 & 2015.......1221

 15. CANADA.......1232   

  A. Market Analysis.......123

Cardiovascular Disease Facts.......123

B. Market Analytics.......123

Table 34: Canadian Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1231

  Table 35: Canadian Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......124
Table 36: Canadian 11-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2005, 2010 & 2015.......1241

 16. JAPAN.......1252   

  Market Analysis.......125

Table 37: Japanese Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1251

  Table 38: Japanese Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......126
Table 39: Japanese 11-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2005, 2010 & 2015.......1261

 17. EUROPE.......1277   

  A. Market Analysis.......127

In Vivo Diagnostics ?Major Segment in CVD Diagnostics Market.......127

Germany - The Largest European Market.......127

Cardiovascular Disease ?Mortality Statistics.......1271

  Table 40: Leading Cause of Death Among Men in Europe (2007): Percentage Breakdown for Cardiovascular Diseases, Poisoning and Injuries, Respiratory Disease, Cancer, and Others (includes corresponding Graph/Chart).......128
Table 41: Leading Cause of Death Among Women in Europe (2007): Percentage Breakdown for Cardiovascular Diseases, Poisoning and Injuries, Respiratory Disease, Cancer, and Others (includes corresponding Graph/Chart).......128

Cardiovascular Disease ?Risk Factor Profile.......1281

  The Cardiovascular Disease Cost Burden.......129

B. Market Analytics.......129

Table 42: European Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1291

  Table 43: European Historic Review for Cardiovascular Disease Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......1301

  Table 44: European Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1311

  Table 45: European Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......1321

  Table 46: European 11-Year Perspective for Cardiovascular Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia & Rest of Europe Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart).......133
Table 47: European 11-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2005, 2010 & 2015.......1331

 17a. FRANCE.......1342   

  Market Analysis.......134

Table 48: French Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1341

  Table 49: French Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......135
Table 50: French 11-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2005, 2010 & 2015.......1351

 17b. GERMANY.......1362   

  Market Analysis.......136

Table 51: German Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1361

  Table 52: German Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......137
Table 53: German 11-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2005, 2010 & 2015.......1371

 17c. ITALY.......1382   

  Market Analysis.......138

Table 54: Italian Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1381

  Table 55: Italian Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......139
Table 56: Italian 11-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2005, 2010 & 2015.......1391

 17d. THE UNITED KINGDOM.......1403   

  A. Market Analysis.......140

UK Cardiovascular Diseases Fact Sheet.......1401

  B. Market Analytics.......141

Table 57: UK Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1411

  Table 58: UK Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......142
Table 59: UK 11-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2005, 2010 & 2015.......1421

 17e. SPAIN.......1432   

  Market Analysis.......143

Table 60: Spanish Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1431

  Table 61: Spanish Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......144
Table 62: Spanish 11-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2005, 2010 & 2015.......1441

 17f. RUSSIA.......1453   

  A. Market Analysis.......145

Major Players.......1451

  B. Market Analytics.......146

Table 63: Russian Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1461

  Table 64: Russian Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......147
Table 65: Russian 11-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2005, 2010 & 2015.......1471

 17g. REST OF EUROPE.......1482   

  Market Analysis.......148

Table 66: Rest of Europe Market for Cardiovascular Disease Diagnostics - Recent Past, Current & Future Market Analysis by Product Segment for In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1481

  Table 67: Rest of Europe Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......149
Table 68: Rest of Europe 11-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2005, 2010 & 2015.......1491

 18. ASIA PACIFIC.......1505   

  A. Market Analysis.......150

Cardiovascular Market in Asia-Pacific.......150

China.......150

Healthcare Expenditure to Grow Considerably by 2015.......1501

  In vitro Diagnostics Market Poised for Strong Growth.......151

Domestic Manufacturers Pose a Threat for Overseas IVD Manufacturers.......151

Leading Players.......151

Cardiovascular Disease Patients Overview.......1511

  Treatment Providers and Hospitals Overview.......152

Hospitals.......152

Table 69: Cardiovascular Special Treatment Hospitals in China: 1991-2011(In numbers) (includes corresponding Graph/Chart).......152

Chinese Cardiovascular Disease Treatment as a Part of Overall Health Care

  Industry.......1521

  Table 70: Cardiovascular Disease Treatment in China: 1991-2006 (includes corresponding Graph/Chart).......153

B. Market Analytics.......153

Table 71: Asia-Pacific Market for Cardiovascular Disease Diagnostics - Recent Past, Current & Future Market Analysis by Product Segment for In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1531

  Table 72: Asia-Pacific Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......154
Table 73: Asia-Pacific 11-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2005, 2010 & 2015.......1541

 19. THE MIDDLE EAST.......1552   

  Market Analysis.......155

Table 74: The Middle East Market for Cardiovascular Disease Diagnostics - Recent Past, Current & Future Market Analysis by Product Segment for In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).......1551

  Table 75: The Middle East Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......156
Table 76: The Middle East 11-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2005, 2010 & 2015.......1561

 20. LATIN AMERICA.......1573   

  A. Market Analysis.......157

Brazil: A Growing Market for IVD.......157

Table 77: Brazilian IVD Market by Segment (2009): Percentage Share Breakdown for Immunoassay, Hormone, Microbiology, Biochemistry, Hematology, Molecular Diagnostics, Cardiac markers, Hemostasis, and Cytology (includes corresponding Graph/Chart).......1571

  B. Market Analytics.......158

Table 78: Latin American Market for Cardiovascular Disease Diagnostics - Recent Past, Current & Future Market Analysis by Product Segment for In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1581

  Table 79: Latin American Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......159


Table 80: Latin American 11-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2000, 2010 & 2015.......1591

COMPETITION305

  Total Companies Profiled: 71 (including Divisions/Subsidiaries - 82)



Region/Country Players

The United States 57 Canada 3Japan 4Europe 15 France 1 Germany 1 The United Kingdom 5 Italy 3 Rest of Europe 5Asia-Pacific (Excluding Japan) 1Middle-East 2



Click here to request a full table of contents and more details on this project.  



 

 

窗体底端


База данных защищена авторским правом ©shkola.of.by 2016
звярнуцца да адміністрацыі

    Галоўная старонка